{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T17:50:35Z","timestamp":1775584235208,"version":"3.50.1"},"reference-count":35,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T00:00:00Z","timestamp":1664928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>(1) Background: Small bowel adenocarcinoma (SBA) is one of the predominant primary small bowel cancers that has a dismal outcome. We aim to report 10 years of experience in SBA management at a regional cancer centre in Canada.; (2) Methods: We retrospectively analysed clinical and pathological data of patients diagnosed with an SBA between 2011 and 2021 at the Ottawa Hospital (TOH), Ottawa, Canada. We describe the clinicopathological features and outcomes, including survival. Potential prognostic factors were analysed using the Cox proportional hazard model for multivariate analysis.; (3) Results: We identified 115 patients with SBA. The duodenum was the most common SBA location representing 61% (70) of the total patients, followed by the jejunum (17%) and ileum (10%). Around 24% (27) of cases presented with bowel obstructions. The majority of patients (56%, 64) had stage IV disease on presentation. Seven patients had MSI-high tumours, while 24% (27) were MS-stable. In terms of management, 48 patients underwent curative surgical resection, 17 of whom received adjuvant chemotherapy. On the other hand, 57 patients (49.5%) with the advanced disease received palliative systemic therapy, and 18 patients (16%) had supportive care only. Over a median follow-up of 21.5 months (range 0\u2013122), the median overall survival was 94, 61, and 34 months for stages II, III, and IV, respectively (p &lt; 0.05). The median recurrence-free survival was 93 and 23 months for stages II and III, respectively. However, there was no statistically significant difference between TNM stages in RFS, p = 0.069. Multivariate Cox regression analysis showed only poor performance status at diagnosis as a predictor for shorter overall survival (p &lt; 0.05). The univariate analysis didn\u2019t show any significant correlation between RFS and covariants.; (4) Conclusions: SBA remains one of the most aggressive tumours with a dismal prognosis even after surgical resection. The optimal chemotherapy regimen has not been established. Further studies are needed to explore the role of adjuvant chemotherapy for stages I-III SBA.<\/jats:p>","DOI":"10.3390\/curroncol29100585","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T01:52:21Z","timestamp":1665193941000},"page":"7439-7449","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Small Bowel Adenocarcinoma: 10-Year Experience in a Cancer Center\u2014The Ottawa Hospital (TOH)"],"prefix":"10.3390","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1904-3775","authenticated-orcid":false,"given":"Abdulhameed","family":"Alfagih","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, The Ottawa Hospital, The University of Ottawa, Ottawa, ON K1H 8L6, Canada"},{"name":"Medical Oncology Department, Comprehensive Cancer Center, King Fahad Medical City, Riyadh 11525, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Alrehaili","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, The Ottawa Hospital, The University of Ottawa, Ottawa, ON K1H 8L6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Asmis","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, The Ottawa Hospital, The University of Ottawa, Ottawa, ON K1H 8L6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.amjsurg.2009.05.037","article-title":"A single-institution experience with 491 cases of small bowel adenocarcinoma","volume":"199","author":"Halfdanarson","year":"2010","journal-title":"Am. J. Surg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/SLA.0b013e31818e4641","article-title":"Small bowel cancer in the United States: Changes in epidemiology, treatment, and survival over the last 20 years","volume":"249","author":"Bilimoria","year":"2009","journal-title":"Ann. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Barsouk, A., Rawla, P., Barsouk, A., and Thandra, K.C. (2019). Epidemiology of Cancers of the Small Intestine: Trends, Risk Factors, and Prevention. Med. Sci., 7.","DOI":"10.3390\/medsci7030046"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4251\/wjgo.v8.i6.509","article-title":"Genetic Risks and Familial Associations of Small Bowel Carcinoma","volume":"8","author":"Shenoy","year":"2016","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/s11605-010-1402-9","article-title":"Intestinal Cancer Risk in Crohn\u2019s Disease: A Meta-Analysis","volume":"15","author":"Laukoetter","year":"2011","journal-title":"J. Gastrointest. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1158\/1078-0432.CCR-05-2452","article-title":"Germ line mutations of mismatch repair genes in hereditary nonpolyposis colorectal cancer patients with small bowel cancer: International society for gastrointestinal hereditary tumours collaborative study","volume":"12","author":"Park","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1245\/s10434-011-2173-6","article-title":"A population-based comparison of adenocarcinoma of the large and small intestine: Insights into a rare disease","volume":"19","author":"Overman","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/sj.bjc.6605449","article-title":"Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine","volume":"102","author":"Overman","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.clinre.2015.09.008","article-title":"Advanced small bowel adenocarcinoma: Molecular characteristics and therapeutic perspectives","volume":"40","author":"Zaaimi","year":"2016","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1080\/00365520410005847","article-title":"Mutational activation of the RAS-RAF-MAPK and the wnt pathway in small intestinal adenocarcinomas","volume":"39","author":"Blaker","year":"2004","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/(SICI)1097-0142(19991215)86:12<2693::AID-CNCR14>3.0.CO;2-U","article-title":"Adenocarcinoma of the small bowel: Review of the national cancer data base, 1985\u20131995","volume":"86","author":"Howe","year":"1999","journal-title":"Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1245\/s10434-020-08926-4","article-title":"Prognostic Role of Mismatch Repair Status, Histotype and High-Risk Pathologic Features in Stage II Small Bowel Adenocarcinomas","volume":"28","author":"Vanoli","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/archsurg.137.5.564","article-title":"Primary Cancers of the Small Bowel: Analysis of Prognostic Factors and Results of Surgical Management","volume":"137","author":"Talamonti","year":"2002","journal-title":"Arch. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/9781118464557.ch31","article-title":"Cancers of the Small Bowel","volume":"345","author":"Raghav","year":"2012","journal-title":"Textb. Uncommon Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00004836-200004000-00017","article-title":"Primary Small Bowel Malignancies: Single-Center Results of Three Decades","volume":"30","author":"Ojha","year":"2000","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/00000658-199703000-00010","article-title":"Malignant small bowel neoplasms: Histopathologic determinants of recurrence and survival","volume":"225","author":"Cunningham","year":"1997","journal-title":"Ann. Surg."},{"key":"ref_18","unstructured":"NCCN (2021). Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Small Bowel Adenocarcinoma, NCCN. Version 2."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.clon.2006.12.001","article-title":"Chemotherapy in Small Bowel Adenocarcinoma: 10-year Experience of the British Columbia Cancer Agency","volume":"19","author":"Czaykowski","year":"2007","journal-title":"Clin. Oncol."},{"key":"ref_20","unstructured":"(2022, May 19). SEER*Explorer: An Interactive Website for SEER Cancer Statistics. Surveillance Research Program NCInstitute, Available online: https:\/\/seer.cancer.gov\/explorer\/."},{"key":"ref_21","unstructured":"(2022, May 24). Statistics Canada. Table 13-10-0111-01 Number and Rates of New Cases of Primary Cancer, by Cancer Type, Age Group and Sex. Available online: https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1310011101."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/01. coc.0000214931.01062.01","article-title":"Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: A retrospective review of 113 cases","volume":"29","author":"Fishman","year":"2006","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Ye, X., Zhang, G., Chen, H., and Li, Y. (2018). Meta-analysis of postoperative adjuvant therapy for small bowel adenocarcinoma. PLoS ONE., 13.","DOI":"10.1371\/journal.pone.0207816"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/jjco\/hyy188","article-title":"Randomized phase III trial of post-operative chemotherapy for patients with stage I\/II\/III small bowel adenocarcinoma (JCOG1502C, J-BALLAD)","volume":"49","author":"Kitahara","year":"2019","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/archsurg.142.3.285","article-title":"Adjuvant concurrent chemoradiation for node-positive adenocarcinoma of the duodenum","volume":"142","author":"Swartz","year":"2007","journal-title":"Arch. Surg."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2407-11-205","article-title":"Systemic chemotherapy for treatment of advanced small bowel adenocarcinoma with prognostic factor analysis: Retrospective study","volume":"11","author":"Koo","year":"2011","journal-title":"BMC Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s10147-020-01703-z","article-title":"Chemotherapy for patients with unresectable or metastatic small bowel adenocarcinoma: A systematic review","volume":"25","author":"Nishikawa","year":"2020","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2008.19.7145","article-title":"Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of vater","volume":"27","author":"Overman","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/CAD.0b013e328350dd0d","article-title":"A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma","volume":"23","author":"Xiang","year":"2012","journal-title":"Anti-Cancer Drugs"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/annonc\/mdq038","article-title":"Chemotherapy of advanced small-bowel adenocarcinoma: A multicenter AGEO study","volume":"21","author":"Zaanan","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1158\/1078-0432.CCR-21-0159","article-title":"ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma","volume":"27","author":"Pedersen","year":"2021","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study","volume":"22","author":"Tournigand","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1245\/s10434-018-6369-x","article-title":"Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases from a Small Bowel Adenocarcinoma: Multi-Institutional Experience","volume":"25","author":"Liu","year":"2018","journal-title":"Ann. Surg. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/10\/585\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:47:03Z","timestamp":1760143623000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/10\/585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,5]]},"references-count":35,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["curroncol29100585"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29100585","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,5]]}}}